Table 2.
WT Vehicle | WT rIFN-γ | TRIF mutant vehicle | TRIF mutant rIFN-γ | |
---|---|---|---|---|
TNF-α | 892 (245) | 760 (57) | 191 (48)** | 501 (115)# |
IL-1β | 7,434 (642) | 4,950 (753)* | 4,168 (731)** | 4,525 (557)** |
IL-6 | 1,914 (451) | 2,030 (624) | 2,446 (398) | 1,507 (216)# |
IL-10 | 14 (2) | 11 (1) | 14 (2) | b.d. |
CXCL1 | 12,586 (1,899) | 9,453 (1,645) | 3,625 (871)** | 4,255 (828)* |
CXCL2 | 20,553 (6,546) | 38,048 (7,157) | 6,432 (1,532)* | 28,943 (5,785)### |
CCL2 | 4,619 (541) | 3,718 (366) | 1,841 (210)*** | 2,126 (240)**' # |
WT and TRIF mutant mice were infected with 1 × 104 CFU K. pneumoniae and 50 ng recombinant IFN-γ was administered intranasally upon infection and after 48 h. Homogenates were prepared from right lungs. Cytokine and chemokine levels are presented in pg/ml of lung homogenate. Data are mean (SE) of 7–8 mice per group. b.d. = Below detection.
p <0.05,
p <0.01,
p <0.001, vs. vehicle-treated WT mice.
p <0.05,
## p <0.01,
p <0.001, rIFN-γ-treated TRIF mutant mice vs. vehicle-treated TRIF mutant mice.